THE MANAGEMENT OF LYMPHOPROLIFERATIVE NEOPLASIA IN FOUR NORTHERN SEA OTTERS (ENHYDRA LUTRIS KENYONI).

IF 0.7 4区农林科学 Q3 VETERINARY SCIENCES Journal of Zoo and Wildlife Medicine Pub Date : 2024-06-01 DOI:10.1638/2022-0096

Michael S McEntire, Karisa N Tang, Matthew R O'Connor, Martin Haulena

{"title":"THE MANAGEMENT OF LYMPHOPROLIFERATIVE NEOPLASIA IN FOUR NORTHERN SEA OTTERS (ENHYDRA LUTRIS KENYONI).","authors":"Michael S McEntire, Karisa N Tang, Matthew R O'Connor, Martin Haulena","doi":"10.1638/2022-0096","DOIUrl":null,"url":null,"abstract":"Lymphoproliferative neoplasia has been reported in both free-ranging sea otters and those in managed care, but little information is available on the management of this neoplastic disease in this species. This case series describes clinical lymphoma in four northern sea otters (Enhydra lutris kenyoni) in managed care. Two otters presented with Stage 5 lymphoma with evidence of hematologic spread resulting in leukemia. Two additional otters presented with Stage 3 disease. Immunophenotypes in these cases included disseminated large B-cell lymphoma and lymphoblastic lymphoma of potential T-cell origin. Cases were managed with multiagent chemotherapy protocols including prednisone, L-asparaginase, cyclophosphamide, vincristine, cytosine arabinoside, lomustine, and doxorubicin. Unique approaches included the use of a vascular access port in one case and development of an autologous vaccine in another. Survival time ranged from 81 to 409 days. Diagnosis, staging, and treatment with multiagent protocols is recommended for the management of lymphoma in sea otters.","PeriodicalId":17667,"journal":{"name":"Journal of Zoo and Wildlife Medicine","volume":null,"pages":null},"PeriodicalIF":0.7000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Zoo and Wildlife Medicine","FirstCategoryId":"97","ListUrlMain":"https://doi.org/10.1638/2022-0096","RegionNum":4,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"VETERINARY SCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Lymphoproliferative neoplasia has been reported in both free-ranging sea otters and those in managed care, but little information is available on the management of this neoplastic disease in this species. This case series describes clinical lymphoma in four northern sea otters (Enhydra lutris kenyoni) in managed care. Two otters presented with Stage 5 lymphoma with evidence of hematologic spread resulting in leukemia. Two additional otters presented with Stage 3 disease. Immunophenotypes in these cases included disseminated large B-cell lymphoma and lymphoblastic lymphoma of potential T-cell origin. Cases were managed with multiagent chemotherapy protocols including prednisone, L-asparaginase, cyclophosphamide, vincristine, cytosine arabinoside, lomustine, and doxorubicin. Unique approaches included the use of a vascular access port in one case and development of an autologous vaccine in another. Survival time ranged from 81 to 409 days. Diagnosis, staging, and treatment with multiagent protocols is recommended for the management of lymphoma in sea otters.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

对四只北方海獭（enhydra lutris kenyoni）淋巴增生性肿瘤的管理。

淋巴组织增生性肿瘤在自由放养的海獭和人工饲养的海獭中都有报道，但有关该物种肿瘤性疾病治疗的信息却很少。本系列病例描述了四只接受管理照料的北方海獭（Enhydra lutris kenyoni）的临床淋巴瘤。其中两只水獭的淋巴瘤已达 5 期，并有血液扩散导致白血病的迹象。另外两只海獭的病情为 3 期。这些病例的免疫分型包括播散性大 B 细胞淋巴瘤和潜在 T 细胞来源的淋巴母细胞淋巴瘤。这些病例采用了多药化疗方案，包括泼尼松、L-天冬酰胺酶、环磷酰胺、长春新碱、阿糖胞苷、洛莫司汀和多柔比星。独特的方法包括在一个病例中使用血管通路端口，以及在另一个病例中开发自体疫苗。存活时间从 81 天到 409 天不等。在治疗海獭淋巴瘤时，建议采用诊断、分期和多试剂方案进行治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of Zoo and Wildlife Medicine 农林科学-兽医学

CiteScore

1.70

自引率

14.30%

发文量

审稿时长

9-24 weeks

期刊介绍： The Journal of Zoo and Wildlife Medicine (JZWM) is considered one of the major sources of information on the biology and veterinary aspects in the field. It stems from the founding premise of AAZV to share zoo animal medicine experiences. The Journal evolved from the long history of members producing case reports and the increased publication of free-ranging wildlife papers. The Journal accepts manuscripts of original research findings, case reports in the field of veterinary medicine dealing with captive and free-ranging wild animals, brief communications regarding clinical or research observations that may warrant publication. It also publishes and encourages submission of relevant editorials, reviews, special reports, clinical challenges, abstracts of selected articles and book reviews. The Journal is published quarterly, is peer reviewed, is indexed by the major abstracting services, and is international in scope and distribution. Areas of interest include clinical medicine, surgery, anatomy, radiology, physiology, reproduction, nutrition, parasitology, microbiology, immunology, pathology (including infectious diseases and clinical pathology), toxicology, pharmacology, and epidemiology.